Maria Ignez Braghiroli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Ignez Braghiroli has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Marcelo Hoff
Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil; Universidade de São Paulo, São Paulo, SP, Brazil
8 shared publications - Alessandro Landskron Diniz
A.C. Camargo Cancer Center, Brazil
5 shared publications - Angelo Alves de Mattos
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
5 shared publications - Antonio Nocchi Kalil
Research and Teaching, Hospital Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil
5 shared publications - Duilio Reis da Rocha Filho
Universidade Federal do Ceará, Brazil
5 shared publications - Flair José Carrilho
Universidade de São Paulo, Brazil
5 shared publications
Latest Publications
- Open Access
Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiation
- Open Access
- 15 May 2026
- Published by FapUNIFESP (SciELO) in SciELO Preprints
- Vol. 39
PREVENTION, SURVEILLANCE, AND EARLY DETECTION OF HEPATOCELLULAR CARCINOMA – A BRAZILIAN MULTIDISCIPLINARY CONSENSUS
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and represents a growing public health challenge. Aims: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of HCC. Methods: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early detection strategies. Recommendation statements were informed by a comprehensive, non-systematic review of the literature conducted using PubMed, Scopus, and the Cochrane Library. Results: Eighteen recommendations reached consensus, covering three main domains: (1) Primary prevention, including HBV vaccination, timely antiviral therapy for viral hepatitis, and lifestyle interventions for metabolic dysfunction. (2) Secondary prevention, outlining risk-based surveillance strategies for patients with advanced fibrosis or cirrhosis due to HBV, HCV, or MASLD. (3) Operational standards for surveillance, emphasizing ultrasound as the cornerstone of monitoring, the importance of structured reporting, management of small nodules, and the selective use of cross-sectional imaging. Conclusions: These multidisciplinary recommendations provide practical, adaptable guidance for HCC prevention, surveillance, and early detection. This guidance document aims to reduce the burden of HCC and support better clinical outcomes across diverse healthcare settings.
- 15 May 2026
- Published by FapUNIFESP (SciELO) in SciELO Preprints
- Vol. 39
Open AccessPREVENTION, SURVEILLANCE, AND EARLY DETECTION OF HEPATOCELLULAR CARCINOMA – A BRAZILIAN MULTIDISCIPLINARY CONSENSUS
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and represents a growing public health challenge. Aims: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of HCC. Methods: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early detection strategies. Recommendation statements were informed by a comprehensive, non-systematic review of the literature conducted using PubMed, Scopus, and the Cochrane Library. Results: Eighteen recommendations reached consensus, covering three main domains: (1) Primary prevention, including HBV vaccination, timely antiviral therapy for viral hepatitis, and lifestyle interventions for metabolic dysfunction. (2) Secondary prevention, outlining risk-based surveillance strategies for patients with advanced fibrosis or cirrhosis due to HBV, HCV, or MASLD. (3) Operational standards for surveillance, emphasizing ultrasound as the cornerstone of monitoring, the importance of structured reporting, management of small nodules, and the selective use of cross-sectional imaging. Conclusions: These multidisciplinary recommendations provide practical, adaptable guidance for HCC prevention, surveillance, and early detection. This guidance document aims to reduce the burden of HCC and support better clinical outcomes across diverse healthcare settings.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Liver resection, transplantation, and local therapies for hepatocellular carcinoma: a Brazilian multidisciplinary consensus
Background: Curative treatment for hepatocellular carcinoma is limited to strategies that achieve complete tumor eradication, primarily liver resection, liver transplantation, and locoregional therapies. However, therapeutic decision-making is complex and must balance tumor burden, liver function, patient characteristics, and resource availability. Aims: To develop multidisciplinary, evidence-based recommendations for the use of surgical and locoregional therapies in hepatocellular carcinoma management. Methods: The Brazilian Society of Surgical Oncology coordinated this consensus in collaboration with 13 additional Brazilian medical societies. A scientific steering committee identified clinically relevant questions addressing indications, patient selection, technical considerations, and outcomes related to liver resection, liver transplantation, and locoregional therapies. Results: A total of 36 clinical questions reached consensus, generating evidence-based recommendations across three major domains: liver resection, including criteria for resectability, assessment of liver functional reserve, and strategies to expand surgical candidacy; liver transplantation, addressing selection criteria, expanded eligibility concepts, donor source considerations, and the role of bridging and downstaging therapies; and locoregional therapies, encompassing ablative and intra-arterial treatments, their indications as definitive, bridging, or alternative strategies, and their integration within multidisciplinary care pathways. Conclusions: This multidisciplinary consensus provides structured, evidence-based guidance on the use of liver resection, liver transplantation, and locoregional therapies in hepatocellular carcinoma management. By addressing key clinical questions about patient selection, therapeutic indications, and integration of curative and locoregional strategies, these recommendations aim to support consistent, informed decision-making in daily clinical practice and to optimize outcomes for patients eligible for potentially curative treatment.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Open AccessLiver resection, transplantation, and local therapies for hepatocellular carcinoma: a Brazilian multidisciplinary consensus
Background: Curative treatment for hepatocellular carcinoma is limited to strategies that achieve complete tumor eradication, primarily liver resection, liver transplantation, and locoregional therapies. However, therapeutic decision-making is complex and must balance tumor burden, liver function, patient characteristics, and resource availability. Aims: To develop multidisciplinary, evidence-based recommendations for the use of surgical and locoregional therapies in hepatocellular carcinoma management. Methods: The Brazilian Society of Surgical Oncology coordinated this consensus in collaboration with 13 additional Brazilian medical societies. A scientific steering committee identified clinically relevant questions addressing indications, patient selection, technical considerations, and outcomes related to liver resection, liver transplantation, and locoregional therapies. Results: A total of 36 clinical questions reached consensus, generating evidence-based recommendations across three major domains: liver resection, including criteria for resectability, assessment of liver functional reserve, and strategies to expand surgical candidacy; liver transplantation, addressing selection criteria, expanded eligibility concepts, donor source considerations, and the role of bridging and downstaging therapies; and locoregional therapies, encompassing ablative and intra-arterial treatments, their indications as definitive, bridging, or alternative strategies, and their integration within multidisciplinary care pathways. Conclusions: This multidisciplinary consensus provides structured, evidence-based guidance on the use of liver resection, liver transplantation, and locoregional therapies in hepatocellular carcinoma management. By addressing key clinical questions about patient selection, therapeutic indications, and integration of curative and locoregional strategies, these recommendations aim to support consistent, informed decision-making in daily clinical practice and to optimize outcomes for patients eligible for potentially curative treatment.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Systemic treatment, response assessment, follow-up, and palliative care in hepatocellular carcinoma – a Brazilian Multidisciplinary Consensus
Background: Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and limited eligibility for curative therapies. Although major advances in systemic treatment and supportive care have occurred, clinical decision-making remains complex owing to inherent heterogeneity among patients with hepatocellular carcinoma. Aims: To record expert opinion on systemic treatment, response assessment, follow-up, and palliative care in hepatocellular carcinoma. Methods: A panel of 43 experts from multiple medical specialties developed clinically relevant questions addressing systemic therapy, response assessment, post-treatment follow-up, and palliative care. Results: Eighteen evidence-based recommendations were formulated, covering indications for systemic therapy across disease stages, selection of first- and second-line treatments, management of patients with impaired liver function, treatment-related toxicities, radiological response assessment, post-treatment surveillance, antiviral management after liver transplantation, and palliative care strategies for patients with advanced disease. Conclusions: This multidisciplinary consensus provides a comprehensive, clinically oriented framework for the management of hepatocellular carcinoma, with particular emphasis on systemic therapy, response assessment, follow-up strategies, and palliative care. Integrating scientific evidence with real-world considerations supports informed, patient-centered decision-making across diverse clinical scenarios.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Open AccessSystemic treatment, response assessment, follow-up, and palliative care in hepatocellular carcinoma – a Brazilian Multidisciplinary Consensus
Background: Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and limited eligibility for curative therapies. Although major advances in systemic treatment and supportive care have occurred, clinical decision-making remains complex owing to inherent heterogeneity among patients with hepatocellular carcinoma. Aims: To record expert opinion on systemic treatment, response assessment, follow-up, and palliative care in hepatocellular carcinoma. Methods: A panel of 43 experts from multiple medical specialties developed clinically relevant questions addressing systemic therapy, response assessment, post-treatment follow-up, and palliative care. Results: Eighteen evidence-based recommendations were formulated, covering indications for systemic therapy across disease stages, selection of first- and second-line treatments, management of patients with impaired liver function, treatment-related toxicities, radiological response assessment, post-treatment surveillance, antiviral management after liver transplantation, and palliative care strategies for patients with advanced disease. Conclusions: This multidisciplinary consensus provides a comprehensive, clinically oriented framework for the management of hepatocellular carcinoma, with particular emphasis on systemic therapy, response assessment, follow-up strategies, and palliative care. Integrating scientific evidence with real-world considerations supports informed, patient-centered decision-making across diverse clinical scenarios.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Diagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a rising incidence largely driven by chronic liver disease. Accurate diagnosis and appropriate clinical assessment at the time of presentation are essential, as therapeutic strategies and prognosis depend on tumor burden, liver function, portal hypertension, and patient performance status. Aim: To develop evidence-based, multidisciplinary recommendations to guide the diagnosis, clinical assessment, and staging of patients with HCC. Methods: This consensus was developed by 43 experts from surgical oncology, hepatology, clinical oncology, radiology, interventional radiology, pathology, liver transplantation, gastroenterology, radiation oncology, and palliative care, under the coordination of the Brazilian Society of Surgical Oncology and 13 collaborating national medical societies. A scientific steering committee predefined clinically relevant questions addressing radiological and histopathological diagnosis, clinical assessment, diagnostic work-up, management of patients at the time of HCC diagnosis, and staging. These questions were discussed and refined in multidisciplinary meetings and submitted to structured voting rounds. Results: The panel formulated 18 recommendations covering key aspects of HCC evaluation, including standardized application of Liver Imaging Reporting and Data System (LI-RADS®) for imaging-based diagnosis, management of indeterminate lesions, indications for biopsy, histopathological classification and reporting, immunohistochemical markers, assessment of hepatic function and portal hypertension, staging systems, diagnostic work-up, and the role of multidisciplinary care. The recommendations emphasize integration of imaging findings with liver-related factors and clinical context to support individualized decision-making. Conclusions: This multidisciplinary consensus provides practical, evidence-based recommendations for the diagnosis, clinical assessment, and staging of HCC. By promoting standardized diagnostic practices while reinforcing comprehensive patient evaluation and multidisciplinary management, this document aims to improve diagnostic accuracy, optimize treatment selection, and support safe care.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 39
Open AccessDiagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a rising incidence largely driven by chronic liver disease. Accurate diagnosis and appropriate clinical assessment at the time of presentation are essential, as therapeutic strategies and prognosis depend on tumor burden, liver function, portal hypertension, and patient performance status. Aim: To develop evidence-based, multidisciplinary recommendations to guide the diagnosis, clinical assessment, and staging of patients with HCC. Methods: This consensus was developed by 43 experts from surgical oncology, hepatology, clinical oncology, radiology, interventional radiology, pathology, liver transplantation, gastroenterology, radiation oncology, and palliative care, under the coordination of the Brazilian Society of Surgical Oncology and 13 collaborating national medical societies. A scientific steering committee predefined clinically relevant questions addressing radiological and histopathological diagnosis, clinical assessment, diagnostic work-up, management of patients at the time of HCC diagnosis, and staging. These questions were discussed and refined in multidisciplinary meetings and submitted to structured voting rounds. Results: The panel formulated 18 recommendations covering key aspects of HCC evaluation, including standardized application of Liver Imaging Reporting and Data System (LI-RADS®) for imaging-based diagnosis, management of indeterminate lesions, indications for biopsy, histopathological classification and reporting, immunohistochemical markers, assessment of hepatic function and portal hypertension, staging systems, diagnostic work-up, and the role of multidisciplinary care. The recommendations emphasize integration of imaging findings with liver-related factors and clinical context to support individualized decision-making. Conclusions: This multidisciplinary consensus provides practical, evidence-based recommendations for the diagnosis, clinical assessment, and staging of HCC. By promoting standardized diagnostic practices while reinforcing comprehensive patient evaluation and multidisciplinary management, this document aims to improve diagnostic accuracy, optimize treatment selection, and support safe care.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 59
The LELEX initiative to enhance cancer imaging communication: development of a consensus-based structured reporting template and lexicon for general oncologic imaging
Objective: The Laudo Estruturado e Léxico em Oncologia (LELEX, Lexicon and Structured Reporting in Oncology) initiative was established to develop a standardized lexicon and structured reporting system applicable across cancer types. Methods: The São Paulo Radiology Society and Brazilian Society of Medical Oncology assembled a 27-member multidisciplinary consensus panel that included radiologists, medical and radiation oncologists, surgeons, and a patient representative. A literature review identified relevant oncologic reporting frameworks to guide the creation of a draft template and lexicon by the LELEX executive committee. Panelists were surveyed to assess current reporting practices and preferences between free-text and structured reports. Consensus (i.e., agreement by more than 80% of panelists) on the final lexicon and reporting system was reached through post-survey panel discussions. Results: Compared with a traditional free-text report, a structured report incorporating the LELEX lexicon received significantly higher ratings for precision and was deemed better for guiding clinical decisions by > 88% of panelists. In post-survey discussions, consensus was achieved for all lexicon components, including diagnostic certainty terms, lesion count descriptors, and longitudinal comparison language. The structured report template was also agreed upon by the panel members. Conclusion: The LELEX initiative established a consensus-driven structured reporting system and lexicon for general oncologic imaging baseline and follow-up assessments.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 59
Open AccessThe LELEX initiative to enhance cancer imaging communication: development of a consensus-based structured reporting template and lexicon for general oncologic imaging
Objective: The Laudo Estruturado e Léxico em Oncologia (LELEX, Lexicon and Structured Reporting in Oncology) initiative was established to develop a standardized lexicon and structured reporting system applicable across cancer types. Methods: The São Paulo Radiology Society and Brazilian Society of Medical Oncology assembled a 27-member multidisciplinary consensus panel that included radiologists, medical and radiation oncologists, surgeons, and a patient representative. A literature review identified relevant oncologic reporting frameworks to guide the creation of a draft template and lexicon by the LELEX executive committee. Panelists were surveyed to assess current reporting practices and preferences between free-text and structured reports. Consensus (i.e., agreement by more than 80% of panelists) on the final lexicon and reporting system was reached through post-survey panel discussions. Results: Compared with a traditional free-text report, a structured report incorporating the LELEX lexicon received significantly higher ratings for precision and was deemed better for guiding clinical decisions by > 88% of panelists. In post-survey discussions, consensus was achieved for all lexicon components, including diagnostic certainty terms, lesion count descriptors, and longitudinal comparison language. The structured report template was also agreed upon by the panel members. Conclusion: The LELEX initiative established a consensus-driven structured reporting system and lexicon for general oncologic imaging baseline and follow-up assessments.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500128
Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study
PURPOSE: Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions. PATIENTS AND METHODS: We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival. RESULTS: Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction–associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS. CONCLUSION: In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500128
Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study
PURPOSE: Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions. PATIENTS AND METHODS: We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival. RESULTS: Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction–associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS. CONCLUSION: In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1883
Simultaneous resection of colorectal cancer and liver metastases
Although the presence of synchronous colorectal liver metastases (CRLM) represents an important prognostic factor for recurrence-free survival (RFS) and overall survival (OS), the definitions of synchronicity are variable in the literature, including metastases at the time of diagnosis, or even before the diagnostic of the primary site of colorectal cancer (CRC), until either six or 12 months after the time of diagnosis, according to the author of each study. Simultaneous approaches to treat CRC and CRLM seem to be safe for patients carefully selected without jeopardizing oncologic outcomes, with similar complication rates, shorter hospital length of stay, and operation times even for major hepatectomies. However, there is no consensus about the optimal timing to approach the primary tumor and CRLM, whether simultaneously or staged, and both performance status and the presence of symptoms play important roles in the treatment sequence, perhaps avoiding two high-risk procedures at the same time.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1883
Open AccessSimultaneous resection of colorectal cancer and liver metastases
Although the presence of synchronous colorectal liver metastases (CRLM) represents an important prognostic factor for recurrence-free survival (RFS) and overall survival (OS), the definitions of synchronicity are variable in the literature, including metastases at the time of diagnosis, or even before the diagnostic of the primary site of colorectal cancer (CRC), until either six or 12 months after the time of diagnosis, according to the author of each study. Simultaneous approaches to treat CRC and CRLM seem to be safe for patients carefully selected without jeopardizing oncologic outcomes, with similar complication rates, shorter hospital length of stay, and operation times even for major hepatectomies. However, there is no consensus about the optimal timing to approach the primary tumor and CRLM, whether simultaneously or staged, and both performance status and the presence of symptoms play important roles in the treatment sequence, perhaps avoiding two high-risk procedures at the same time.
- Open Access
- 15 July 2024
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 20 (CP)
Unveiling the Landscape of Brazilian Clinical Oncologists: Challenges, Diversity, and Quality Care
Cancer remains a significant public health challenge in Brazil, with an estimated 704 thousand new cases annually. Clinical oncology, a pivotal specialty in cancer diagnosis and treatment, has evolved since its formal establishment in 1946. Recent recognition by the Brazilian Federal Board of Medicine solidified its status, culminating in normative resolution nr. 2,162/2017. The present study aims to characterize Brazilian clinical oncologists and analyze their epidemiological and structural contexts using data from the Brazilian Society of Clinical Oncology's 2023 census and secondary sources, including the National Cancer Institute (Instituto Nacional de Câncer [INCA], in Portuguese) and Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatistica [IBGE], in Portuguese). A cross-sectional design employing qualitative-quantitative methods surveyed 761 clinical oncologists, revealing insights into demographics, workload, stress levels, and challenges. The results highlight regional disparities in cancer mortality rates despite the concentration of oncology services in the South and Southeast. Challenges include access to new treatments, late diagnoses, and systemic underfunding. Moreover, this study underscores gender and racial disparities within the specialty, indicating a predominantly white and heterosexual profile among practitioners. Addressing these issues is crucial for enhancing healthcare equity and improving patients' outcomes in oncology practice.
- 15 July 2024
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 20 (CP)
Open AccessUnveiling the Landscape of Brazilian Clinical Oncologists: Challenges, Diversity, and Quality Care
Cancer remains a significant public health challenge in Brazil, with an estimated 704 thousand new cases annually. Clinical oncology, a pivotal specialty in cancer diagnosis and treatment, has evolved since its formal establishment in 1946. Recent recognition by the Brazilian Federal Board of Medicine solidified its status, culminating in normative resolution nr. 2,162/2017. The present study aims to characterize Brazilian clinical oncologists and analyze their epidemiological and structural contexts using data from the Brazilian Society of Clinical Oncology's 2023 census and secondary sources, including the National Cancer Institute (Instituto Nacional de Câncer [INCA], in Portuguese) and Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatistica [IBGE], in Portuguese). A cross-sectional design employing qualitative-quantitative methods surveyed 761 clinical oncologists, revealing insights into demographics, workload, stress levels, and challenges. The results highlight regional disparities in cancer mortality rates despite the concentration of oncology services in the South and Southeast. Challenges include access to new treatments, late diagnoses, and systemic underfunding. Moreover, this study underscores gender and racial disparities within the specialty, indicating a predominantly white and heterosexual profile among practitioners. Addressing these issues is crucial for enhancing healthcare equity and improving patients' outcomes in oncology practice.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 37, e1869
FROM ONCOLOGIST TO SURGEON - GENETICS IN COLORECTAL METASTASIS FOR SURGEONS
Colorectal cancer (CRC) is a common disease, with incidence in Brazil of 45,630 new cases per 100,000 inhabitants between 2023-2025. Risk factors for CRC can be evaluated between environmental and hereditary and their mode of presentation are classified as sporadic, inherited and familial. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. The percentage of patients with a true hereditary genetic predisposition is less than 10%, and these are related to the presence or absence of colonic polyps as an important manifestation of the disease. Non-polyposis diseases are known as hereditary non-polypomatous colorectal cancer (HNPCC) or Lynch syndrome, and polyposis diseases are familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and hamartomatous polyposis syndromes (e.g., Peutz-Jeghers, juvenile polyposis, phosphatase and tensin homologue - PTEN, Cowden syndrome). These diseases are linked to a high risk of developing cancer. With the development of treatments in metastatic disease and the use of targeted therapies and their biomarkers, it was possible to evaluate them within clinical studies both in the primary tumor and in the correspondence of metastases.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 37, e1869
Open AccessFROM ONCOLOGIST TO SURGEON - GENETICS IN COLORECTAL METASTASIS FOR SURGEONS
Colorectal cancer (CRC) is a common disease, with incidence in Brazil of 45,630 new cases per 100,000 inhabitants between 2023-2025. Risk factors for CRC can be evaluated between environmental and hereditary and their mode of presentation are classified as sporadic, inherited and familial. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. The percentage of patients with a true hereditary genetic predisposition is less than 10%, and these are related to the presence or absence of colonic polyps as an important manifestation of the disease. Non-polyposis diseases are known as hereditary non-polypomatous colorectal cancer (HNPCC) or Lynch syndrome, and polyposis diseases are familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and hamartomatous polyposis syndromes (e.g., Peutz-Jeghers, juvenile polyposis, phosphatase and tensin homologue - PTEN, Cowden syndrome). These diseases are linked to a high risk of developing cancer. With the development of treatments in metastatic disease and the use of targeted therapies and their biomarkers, it was possible to evaluate them within clinical studies both in the primary tumor and in the correspondence of metastases.